Figures cited from a ClinicalTrials.gov LATAM facility sweep (API pull 1 September 2026, 6:32 PM ET) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANMAT, ethics, and FDA rules with qualified advisers. We name only the facility strings and example NCT IDs those sources support. We do not invent a principal investigator. We do not claim Hospital Alemán Buenos Aires as a bioaccess® client.
If you searched Hospital Aleman Buenos Aires first-in-human, Hospital Alemán CABA clinical trial, Hospital Alemán CRO Argentina, or “go direct Hospital Alemán Buenos Aires,” you followed a campus string ClinicalTrials.gov still publishes. Hospital Aleman in Buenos Aires, Argentina, is a real named hospital string on ClinicalTrials.gov. It is not a first-in-human medical-device CRO, and it is not the operator of the ANMAT file.
bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns ANMAT, institutional ethics, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.
This page is the named Buenos Aires hospital. It is not Hospital Alemão Oswaldo Cruz (São Paulo), not Hospital Italiano de Buenos Aires, and not Hospital Británico. Sharing “Alemán / Alemão” or sharing Buenos Aires is not a license to collapse them. City-label aliases Hospital Aleman Caba / CABA / Ciudad Autónoma stay on this page; we do not ship a second page.
Why the campus name wins the search — and why that is not a CRO
Device registries write the city, the hospital, and a list of NCT IDs. They rarely write the CRO. On the 1 September 2026 ClinicalTrials.gov LATAM sweep (interventional studies; all years), this campus sits here after filters:
Counts are unique NCT IDs from a ClinicalTrials.gov sweep of Latin American facilities pulled 1 September 2026.
- Hospital Aleman (Buenos Aires, Argentina) — canonical NCT string: ALL interventional n=22; DEVICE n=0. Example NCT IDs: NCT00496002, NCT00496158, NCT00940095.
- City-label alias Hospital Aleman (Caba): ALL n=11. Listed separately. Same page. No combined total.
- City-label alias Hospital Aleman (CABA): ALL n=10. Listed separately. Same page. No combined total. A CABA DEVICE n=6 label is listed separately as well; we do not invent a combined unique-study total with canonical DEVICE n=0.
These counts are not added together. Ciudad Autónoma city-label strings stay on this page.
Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.
We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.
That is the leak: a founder searching “Hospital Alemán Buenos Aires first-in-human” or “Hospital Aleman CABA clinical trial” finds canonical ALL n=22 (DEVICE n=0) without finding ANMAT, ethics, import, insurance, or 21 CFR 812.28 — and without landing on Hospital Alemão Oswaldo Cruz, HIBA, or Británico. A named hospital is still a site. An NCT location row is not a CRO.
The site is the site. The CRO is the operator.
A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.
What the hospital can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing service line.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the hospital is not built to own for an investigational device:
- ANMAT. Argentina’s national medicines and devices authority (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the file a sponsor actually needs. A hallway conversation on this campus is not that file. A published statutory target on the trial side is 90 business days and the clock pauses for RFIs. Trial authorization and commercial registro are separate petitions. A hallway conversation at Hospital Alemán is not an Oswaldo Cruz São Paulo file, not a HIBA file, and not a Británico file.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a campus-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The site may run visits. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.
Going direct to this campus is how you confirm a room. It is not how you open an investigational file.
How ANMAT actually works (the short version)
Use live bioaccess® Argentina / ANMAT pages for the full pathway. Trial authorization and commercial registro are different petitions. Do not put both on one Gantt labeled “Argentina.” A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs; ask for a protocol-specific calendar rather than treating an NCT row as start-up.
Ask for a protocol-specific calendar. A hospital email is not ANMAT clearance. bioaccess® manages the file. That is CRO work, not site work.
All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Not a critique of the hospital
Hospital Aleman is a serious named Buenos Aires hospital on the public registry. ALL n=22 is registry volume, not a punchline. We do not invent a DEVICE n for the canonical string. It is separate from Hospital Alemão Oswaldo Cruz, HIBA, or Británico. Use the site when the protocol fits. Hire the operator.
What the CRO still does after you have the campus on a slide
- Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the ANMAT / ethics packet.
- Importer of record and device accountability.
- Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a campus string.
Colombia is still on the map
A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on Clinical Trials in Panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I contract Hospital Alemán Buenos Aires directly for a device FIH?
You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your ANMAT applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run the NCT IDs listed here?
No public bioaccess® case-study page names this hospital. We will not invent that claim. This page answers the search; it does not claim the studies.
Is this the same page as Hospital Alemão Oswaldo Cruz, Hospital Italiano de Buenos Aires, or Hospital Británico?
No. Hospital Alemão Oswaldo Cruz has its own page in São Paulo. HIBA has its own page. Británico has its own page. This page is Hospital Aleman, Buenos Aires only. Caba ALL n=11 and CABA ALL n=10 stay listed separately; we do not combine them.
Should I add canonical ALL n=22, Caba ALL n=11, and CABA ALL n=10?
No. Alias n is listed separately. A combined unique-study total is not published. Caba / CABA / Ciudad Autónoma city-label strings stay on this page.
Is this Hospital Alemão Oswaldo Cruz?
No. That is Hospital Alemão Oswaldo Cruz in São Paulo. German-hospital naming in another country is not a merge. Overlap on that live page is not a reason to repeat it here.
Why DEVICE n=0 on the canonical string?
That is the ranking-table DEVICE count for Hospital Aleman, Buenos Aires. A separate CABA DEVICE n=6 label is listed separately; we do not combine them it onto canonical DEVICE n=0. ALL n=22 is still not ANMAT authorization. A published statutory target on the trial side is on the order of 90 business days and pauses for RFIs. Trial versus registro remain different petitions.
Did bioaccess® run NCT00496002?
No. We cite it as facility evidence for this string. We will not invent a sponsor or a PI. We will not claim bioaccess® ran it.
Next step
If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Buenos Aires siblings (do not merge): Hospital Italiano de Buenos Aires, Hospital Británico. São Paulo sibling (do not merge): Hospital Alemão Oswaldo Cruz.
Julio G. Martinez-Clark, CEO · bioaccess®